Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Trial details
- Registry ID
- NCT04802837
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Vancomycin oral
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsNCT04802837 | Summit Therapeutics | Phase 3 | Terminated | 2021-09-17Actual |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542 | ACXP | Phase 2 | Completed | 2023-10-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |